2023Äê6ÔÂ16ÈÕµÚ68½ìÈÕ±¾Í¸Îöҽѧ»áÄê»á×¼ÆÚÔÚÈÕ±¾Éñ»§¾ÙÐУ¬£¬£¬£¬£¬£¬±¾½ì´ó»áÖ÷ÌâΪ¡°ÖªÐкÏÒ»£ºÊÖÒÕÔËÓúÍѧÒÔÖÂÓᱡ£¡£¡£¡£¡£¡£¡£Ã¿Äê»áÓÐ͸ÎöÁìÓòÔ¼2ÍòרҵÈËÊ¿²Î»á½»Á÷×îÐÂ͸ÎöÇ°ÑØÊÖÒÕÓëÁÆ·¨¡£¡£¡£¡£¡£¡£¡£ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©ÔÊÐíÒýÈëµÄ½µÁ×Ò©ÎïTenapanor£¨ÌæÄÉÅÁŵ£©Öйú3ÆÚÊý¾Ý£¨TEN C-03-002 Ñо¿£©ÈëÑ¡´ó»á¿ÚÍ·»ã±¨£¬£¬£¬£¬£¬£¬±±¾©´óѧÈËÃñÒ½Ôº¸ÊÁ¼Ó¢½ÌÊÚ½«´ú±íÑо¿×é×÷ΪÑݽ²ÕßÔÚÄê»áʱ´ú¾ÍÑо¿ÏêϸÊý¾ÝÓëÒµÄÚÙÉÐн»Á÷¡£¡£¡£¡£¡£¡£¡£

»ã±¨³¡´Î: Oral Presentation Session 3 ʱ¼ä£º2023Äê6ÔÂ16ÈÕ 10:30-11:20

ͼƬȪԴ£ºhttps://www.jsdt.or.jp/

TenapanorÊÇÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©´ÓArdelyx£¬£¬£¬£¬£¬£¬IncÔÊÐíÒýÈëµÄÒ»¿î¿Ú·þ³¦µÀÄÆ/Çâ½»Á÷Ìå3£¨NHE3£©ÒÖÖƼÁ£¬£¬£¬£¬£¬£¬ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©»ñÔÊÐíÈÏÕæ¸Ã¿îÐÂÒ©ÔÚÖк£Äڵء¢Ïã¸ÛÌØÇø¼°°ÄÃÅÌØÇøµÄ¶À¼ÒÁÙ´²¿ª·¢ºÍÉÌÒµ»¯µÈȨÒæ¡£¡£¡£¡£¡£¡£¡£Tenapanor¿ÉÒÔïÔÌ­³¦µÀÄÆÀë×ÓÎüÊÕ£¬£¬£¬£¬£¬£¬ÔöÌí³¦Ç»ÄÚË®·Ö£¬£¬£¬£¬£¬£¬Ôö½ø³¦µÀÈ䶯ºÍÕý³£ÅűãµÄƵÂÊ£¬£¬£¬£¬£¬£¬2019ÄêÒѱ»ÃÀ¹úFDAÅú×¼ÓÃÓÚ³ÉÈ˱ãÃØÐͳ¦Ò×¼¤×ÛºÏÕ÷µÄÖÎÁÆ¡£¡£¡£¡£¡£¡£¡£±ðµÄ£¬£¬£¬£¬£¬£¬Ñо¿·¢Ã÷Tenapanor»¹ÄÜÒÖÖƳ¦µÀϸ°ûÅÔ;¾¶Á×ËáÑεÄÎüÊÕ£¬£¬£¬£¬£¬£¬´Ó¶ø½µµÍѪÁס£¡£¡£¡£¡£¡£¡£Ä¿½ñTenapanorÓÃÓÚÖÕÄ©ÆÚÉö²¡(ESRD)»¼Õ߸ßÁ×Ѫ֢µÄÖÎÁÆÓ¦ÓÃÒ²ÔÚÆ𾢿ª·¢ÖС£¡£¡£¡£¡£¡£¡£¶àÏîÃÀ¹úºÍÈÕ±¾µÄ¢ò¡¢¢óÆÚÑо¿Åú×¢Tenapanor¿ÉÏÔÖø½µµÍѪҺ͸Îö»¼ÕßÉý¸ßµÄѪÁ×(sP)ˮƽ£¬£¬£¬£¬£¬£¬ÔÚ³¤´ï52ÖܵÄÓÃÒ©ÊÔÑéÖÐÒ²ÏÔʾËüµÄÖÎÁÆ¿ÉÄÍÊÜÐÔ^1,2,3¡£¡£¡£¡£¡£¡£¡£

TEN C-03-002 Ñо¿£¨Ñо¿¹ÒºÅºÅ£ºCTR20202588£©ÊÇÒ»ÏîÔÚÖйú¿ªÕ¹µÄTenapanorÖÎÁÆESRDѪҺ͸Îö»¼Õ߸ßÁ×Ѫ֢µÄÓÐÓÃÐÔºÍÇå¾²ÐÔµÄËæ»ú¡¢Ë«Ã¤¡¢Î¿½å¼Á±ÈÕÕ¡¢¶àÖÐÐÄ¢óÆÚÁÙ´²Ñо¿¡£¡£¡£¡£¡£¡£¡£Ñо¿ÄÉÈëÁË150Àýά³ÖÐÔѪҺ͸Îö»¼ÕßÒÔ2:1µÄ±ÈÀýËæ»ú½ÓÊÜ30 mg Bid Tenapanor »òο½å¼ÁÖÎÁÆ4ÖÜ¡£¡£¡£¡£¡£¡£¡£Ö÷ÒªÁÆЧָ±êΪÒâÏòÖÎÁÆÆÊÎö£¨ITT£©ÈËȺÖÐTenapanor×é±ÈÕÕο½å¼Á×éÔÚ4ÖÜÖÎÁÆÆÚ¿¢Ê·ÃÊÓ»òÌáÇ°ÖÕÖ¹·ÃÊÓʱ£¨Ñо¿Öյ㣩µÄѪÁ×ˮƽ½Ï»ùÏßת±äµÄ²î±ð¡£¡£¡£¡£¡£¡£¡£ÔÚÑо¿ÖÕµãʱ£¬£¬£¬£¬£¬£¬Tenapanor×é±ÈÕÕο½å¼Á×éµÄѪÁ×ˮƽ½Ï»ùÏßת±äµÄ×îС¶þ³Ë¾ùÖµ²î±ðΪ-1¡¤17 mg/dL (95% CI: -1¡¤694, -0¡¤654, p<0¡¤001)£¬£¬£¬£¬£¬£¬Á½×é»®·ÖÓÐ44.59%ºÍ10.14%µÄ»¼ÕßµÖ´ïÁËѪÁ×ˮƽ<5.5 mg/dLµÄÄ¿µÄ¡£¡£¡£¡£¡£¡£¡£ÔÚÄêËê(<45 Ëê¡¢¡Ý45~£¼65 Ëê¡¢¡Ý65 Ëê)¡¢ÐÔ±ðºÍ»ùÏßѪÁ×ˮƽ(<7.5 mg/dL»ò¡Ý7.5 mg/dL)µÄÑÇ×éÆÊÎöÖУ¬£¬£¬£¬£¬£¬Tenapanor×é½Ï»ùÏßsPˮƽµÄ½µµÍ¶¼ÓÅÓÚο½å¼Á×é¡£¡£¡£¡£¡£¡£¡£½ÓÊÜTenapanorºÍο½å¼ÁÖÎÁƵĻ¼ÕßÖл®·ÖÓÐ51.9%ºÍ41.1%µÄ»¼Õß±¨¸æÁËÖÎÁÆʱ´ú·ºÆðµÄ²»Á¼ÊÂÎñ(TEAEs)£¬£¬£¬£¬£¬£¬ÑÏÖØˮƽ¶àΪÇáÖжÈ¡£¡£¡£¡£¡£¡£¡£¸ÃÑо¿Ð§¹ûÓë¼ÈÍùÃÀ¹ú¡¢ÈÕ±¾Ñо¿Ð§¹ûÒ»Ö¡£¡£¡£¡£¡£¡£¡£

ÔÚAMPLIFYÑо¿ÖУ¬£¬£¬£¬£¬£¬TenapanorºÍÁ×ÍŽá¼ÁµÄÍŽáÖÎÁƽøÒ»²½¸ÄÉÆÁ˸ßÁ×Ѫ֢µÄ¿ØÖÆ⁴¡£¡£¡£¡£¡£¡£¡£´ËÇ°ÁíÒ»ÏîÈÕ±¾Ñо¿Ò²Ö¤ÊµÌí¼ÓTenapanor²»µ«¿ÉÒÔЭͬ½µµÍѪÁ×£¬£¬£¬£¬£¬£¬»¹ÄÜÏÔÖø½µµÍÓëÁ×ÍŽá¼ÁÏà¹ØµÄҩƬ·þÓü縺⁵¡£¡£¡£¡£¡£¡£¡£±ðµÄ£¬£¬£¬£¬£¬£¬ÔÚÈËÌåÊÔÑéÖÐûÓÐÊӲ쵽Á×ÍŽá¼ÁºÍTenapanorÖ®¼ä±£´æÁÙ´²Ïà¹ØµÄÒ©ÎïÏ໥×÷ÓÃ⁶¡£¡£¡£¡£¡£¡£¡£ËäÈ»º£ÄÚÆÕ±éʹÓÃÁ×ÍŽá¼Á£¬£¬£¬£¬£¬£¬¿ÉÊÇÈÔÓд󲿷Ö͸Îö»¼ÕßµÄѪÁ׿ØÖÆδ´ïKDIGOÖ¸ÄÏÍƼöµÄÄ¿µÄˮƽ¡£¡£¡£¡£¡£¡£¡£ÏÖÓеÄÁ×ÍŽá¼Á»úÖÆÀàËÆ£¬£¬£¬£¬£¬£¬Ò»Î¶µÄ¼ÓÒ©²¢²»¿É´øÀ´¸üºÃµÄÁÆЧ£»£»£»£»£»ÇÒÁ×ÍŽá¼Á賦µÀ²»Á¼·´Ó¦±¬·¢Âʸߡ¢·þҩƬÊý¶à£¨Ñо¿Åú×¢¾ÙÐÐ͸ÎöµÄCKD¸ßÁ×Ѫ֢»¼Õßƽ¾ùÁ×ÍŽá¼Á·þҩƬÊýÔ¼11Ƭ/ÈÕ⁷£©£¬£¬£¬£¬£¬£¬µ¼Ö»¼ÕßÒÀ´ÓÐԽϲî¡£¡£¡£¡£¡£¡£¡£Tenapanor×÷ΪһÖÖÔÚÑеÄÐÂÐͽµÁ×Ò©ÎïÒ»Ö±±¸ÊÜÆÚ´ý£¬£¬£¬£¬£¬£¬¸Ãҩͨ¹ýÒÖÖÆϸ°ûÅÔ;¾¶Á×ËáÑεÄÎüÊÕµÖ´ï½µµÍѪÁ×µÄÄ¿µÄ£¬£¬£¬£¬£¬£¬ÆäҩƬÌå»ýС£¡£¡£¡£¡£¡£¡£¬£¬£¬£¬£¬£¬·þÓü縺С£¡£¡£¡£¡£¡£¡£¬£¬£¬£¬£¬£¬ÇÒ½µÁ×µÄͬʱ»¹¿ÉÒÔʹ´ó±ãËÉÈí£¬£¬£¬£¬£¬£¬¸ÄÉƱãÃصÄÖ¢×´¡£¡£¡£¡£¡£¡£¡£TenapanorÖйú3ÆÚЧ¹ûΪÆäδÀ´ÔÚÖйú͸Îö»¼ÕßÖоÙÐнµÁ×ÖÎÁÆÌṩÁËÖ¤¾Ý»ù´¡£¡£¡£¡£¡£¡£¡£¬£¬£¬£¬£¬£¬×÷ΪһÖÖµ¥¶ÀʹÓúͿÉÓëÏÖÓÐÁ×ÍŽá¼ÁЭͬʹÓõÄÐÂÐͽµÁ×ÖÎÁÆÒ©Î£¬£¬£¬£¬£¬ÆÚ´ýδÀ´ÔÚÖйúÉÏÊв¢ÎªÖйú»¼Õß´øÀ´¸ü¶à»ñÒæ¡£¡£¡£¡£¡£¡£¡£

¹ØÓÚÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©

ÉϺ£ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©£¨¼¯ÍÅ£©¹É·ÝÓÐÏÞ¹«Ë¾£¨¡°ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©¡±£¬£¬£¬£¬£¬£¬¹ÉƱ´úÂ룺600196.SH£¬£¬£¬£¬£¬£¬02196.HK£©½¨ÉèÓÚ1994 Ä꣬£¬£¬£¬£¬£¬ÊÇÒ»¼ÒÖ²¸ùÖйú¡¢Á¢ÒìÇý¶¯µÄÈ«Çò»¯Ò½Ò©¿µ½¡¹¤Òµ¼¯ÍÅ£¬£¬£¬£¬£¬£¬Ö±½ÓÔËÓªµÄÓªÒµ°üÀ¨ÖÆÒ©¡¢Ò½ÁÆÆ÷еÓëҽѧÕï¶Ï¡¢Ò½ÁÆ¿µ½¡Ð§ÀÍ£¬£¬£¬£¬£¬£¬²¢Í¨¹ý²Î¹É¹úÒ©¿Ø¹ÉÁýÕÖµ½Ò½Ò©ÉÌÒµÁìÓò¡£¡£¡£¡£¡£¡£¡£

ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©ÒÔ»¼ÕßΪÖÐÐÄ¡¢ÁÙ´²ÐèÇóΪµ¼Ïò£¬£¬£¬£¬£¬£¬Í¨¹ý×ÔÖ÷Ñз¢¡¢ÏàÖú¿ª·¢¡¢ÔÊÐíÒý½ø¡¢Éî¶È·õ»¯µÄ·½·¨£¬£¬£¬£¬£¬£¬Ò»Á¬¸»ºñÁ¢Òì²úÆ·¹ÜÏߣ¬£¬£¬£¬£¬£¬ÌáÉýFIC£¨First-in-class£¬£¬£¬£¬£¬£¬¼´Í¬ÀàÊ×´´£©ÓëBIC£¨Best-in-class£¬£¬£¬£¬£¬£¬¼´Í¬Àà×î¼Ñ£©ÐÂÒ©µÄÑо¿ÓëÁÙ´²¿ª·¢ÄÜÁ¦£¬£¬£¬£¬£¬£¬¼ÓËÙÁ¢ÒìÊÖÒպͲúÆ·µÄÑз¢ºÍת»¯ÂäµØ¡£¡£¡£¡£¡£¡£¡£

ÔÚ¡°4IN¡±£¨Á¢Òì Innovation¡¢¹ú¼Ê»¯ Internationalization¡¢ÖÇÄÜ»¯ Intelligentization¡¢ÕûºÏ Integration£©µÄÕ½ÂÔÖ¸µ¼Ï£¬£¬£¬£¬£¬£¬ÈËÉú¾ÍÊDz«(ZLKS)¼¯ÍÅΨһ¹Ù·½ÍøÕ¾Ò½Ò©³Ð¼Ì¡°Á¢ÒìתÐÍ¡¢ÕûºÏÔËÓª¡¢ÎȽ¡ÔöÌí¡±µÄÉú³¤Ä£Ê½ÒÔ¼°Îª¹É¶«´´Á¢¼ÛÖµµÄÐÅÐÄ£¬£¬£¬£¬£¬£¬Ò»Ö±ÔöÇ¿×ÔÖ÷Ñз¢ÓëÍⲿÏàÖú£¬£¬£¬£¬£¬£¬¸»ºñ²úÆ·¹ÜÏߣ¬£¬£¬£¬£¬£¬Ç¿»¯È«Çò»¯½á¹¹£¬£¬£¬£¬£¬£¬ÌáÉýÔËӪЧÂÊ£¬£¬£¬£¬£¬£¬Í¬Ê±£¬£¬£¬£¬£¬£¬Æð¾¢ÍƽøÒ½ÁÆ¿µ½¡¹¤ÒµÏßÉÏÏßϽṹ£¬£¬£¬£¬£¬£¬ÖÂÁ¦ÓÚ³ÉΪȫÇòÒ½ÁÆ¿µ½¡Êг¡µÄÒ»Á÷ÆóÒµ¡£¡£¡£¡£¡£¡£¡£

ÉóÅúºÅ£ºNP-MA-20230605-CN-TEN-00002

1.????? Block GA, Rosenbaum DP, Yan A, Chertow GM. Efficacy and Safety of Tenapanor in Patients with Hyperphosphatemia Receiving Maintenance Hemodialysis: A Randomized Phase 3 Trial. J Am Soc Nephrol 2019; 30: 641¨C52.

2.????? Inaba M, Une Y, Ikejiri K, Kanda H, Fukagawa M, Akizawa T. Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan-A Phase 2 Randomized Trial. Kidney Int Rep 2021; 7: 177¨C88.

3.????? Block GA, Bleyer AJ, Silva AL, et al. Safety and Efficacy of Tenapanor for Long-term Serum Phosphate Control in Maintenance Dialysis: A 52-Week Randomized Phase 3 Trial (PHREEDOM). Kidney360 2021; 2: 1600¨C10.

4.????? Pergola PE, Rosenbaum DP, Yang Y, Chertow GM. A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY). J Am Soc Nephrol 2021; 32: 1465¨C73.

5.????? Shigematsu T, Une Y, Ikejiri K, Kanda H, Fukagawa M, Akizawa T. Therapeutic Effects of Add-On Tenapanor for Hemodialysis Patients with Refractory Hyperphosphatemia. Am J Nephrol 2021; 52: 496¨C506.

6.????? Johansson S, Leonsson-Zachrisson M, Knutsson M, et al. Preclinical and Healthy Volunteer Studies of Potential Drug-Drug Interactions Between Tenapanor and Phosphate Binders. Clin Pharmacol Drug Dev 2017; 6: 448¨C56.

7.????? Steven N Fishbane, et al. Phosphate Absorption and Hyperphosphatemia Management in Kidney Disease: A Physiology-Based Review. Kidney Med. 2021 Aug 27;3(6):1057-1064.